foxo4 dri senolytic peptide human trial 2024 2025 Buy FOXO4-DRI (Proxofim) Peptide Inhibitors Targeting FOXO4-p53 Interactions
Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7





